KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Petmed Express (PETS) EBITDA (2016 - 2025)

Petmed Express has reported EBITDA over the past 16 years, most recently at -$10.5 million for Q4 2025.

  • For Q4 2025, EBITDA fell 2226.44% year-over-year to -$10.5 million; the TTM value through Dec 2025 reached -$59.0 million, down 10032.83%, while the annual FY2025 figure was $3.6 million, 216.59% up from the prior year.
  • EBITDA for Q4 2025 was -$10.5 million at Petmed Express, down from -$8.4 million in the prior quarter.
  • Over five years, EBITDA peaked at $9.0 million in Q1 2021 and troughed at -$34.1 million in Q2 2025.
  • A 5-year average of -$529450.0 and a median of $645000.0 in 2023 define the central range for EBITDA.
  • Biggest five-year swings in EBITDA: surged 1074.67% in 2024 and later plummeted 2226.44% in 2025.
  • Year by year, EBITDA stood at $5.9 million in 2021, then tumbled by 97.06% to $172000.0 in 2022, then tumbled by 858.14% to -$1.3 million in 2023, then soared by 65.49% to -$450000.0 in 2024, then plummeted by 2226.44% to -$10.5 million in 2025.
  • Business Quant data shows EBITDA for PETS at -$10.5 million in Q4 2025, -$8.4 million in Q3 2025, and -$34.1 million in Q2 2025.